First, we compared BPTF and c-MYC levels with the activation of c-MYC signatures in a collection of 20 expression data sets from Oncomine and Gene Expression Omnibus (GEO) encompassing human tumours of diverse origin (Supplementary Data 9) driven by different MYC family members: Burkitt lymphoma (BL), colorectal, prostate and pancreatic tumours are mainly driven by c-MYC34, 35, 36, whereas medulloblastoma and ovarian carcinoma commonly show amplification and/or overexpression of N-MYC and L-MYC, respectively37, 38. The gene discussed is MYCN; the disease is medulloblastoma.